Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
3.88 (1y: -45%)
Market Cap 617.7 M P/E(ttm)
Enterprise Value 933.65 M P/B 17.90
DNDN- NAS (USA)
Dendreon Corp
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$3.88
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry		 vs
history
Cash to Debt 0.602
DNDN's Cash to Debt is ranked lower than
84% of the 388 Companies
in the Global Biotechnology industry.

( Industry Median: 52.90 vs. DNDN: 0.602 )
DNDN' s 10-Year Cash to Debt Range
Min: 0.6   Max: 48.87
Current: 0.6
0.6
48.87
Equity to Asset 0.048
DNDN's Equity to Asset is ranked lower than
98% of the 348 Companies
in the Global Biotechnology industry.

( Industry Median: 0.58 vs. DNDN: 0.048 )
DNDN' s 10-Year Equity to Asset Range
Min: 0.05   Max: 0.91
Current: 0.05
0.05
0.91
F-Score: 1
Z-Score: -3.61
M-Score: -2.68
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry		 vs
history
Operating margin (%) -104.40
DNDN's Operating margin (%) is ranked lower than
675675% of the 148 Companies
in the Global Biotechnology industry.

( Industry Median: 13.90 vs. DNDN: -104.40 )
DNDN' s 10-Year Operating margin (%) Range
Min: -99050.5   Max: -85.4
Current: -104.4
-99050.5
-85.4
Net-margin (%) -120.9
DNDN's Net-margin (%) is ranked lower than
671140% of the 149 Companies
in the Global Biotechnology industry.

( Industry Median: 13.50 vs. DNDN: -120.9 )
DNDN' s 10-Year Net-margin (%) Range
Min: -217981   Max: -98.9
Current: -120.9
-217981
-98.9
ROE (%) -1137.2
DNDN's ROE (%) is ranked lower than
689654% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 9.80 vs. DNDN: -1137.2 )
DNDN' s 10-Year ROE (%) Range
Min: -1137.2   Max: -18.8
Current: -1137.2
-1137.2
-18.8
ROA (%) -54.6
DNDN's ROA (%) is ranked lower than
675675% of the 148 Companies
in the Global Biotechnology industry.

( Industry Median: 6.70 vs. DNDN: -54.6 )
DNDN' s 10-Year ROA (%) Range
Min: -72.8   Max: -14.7
Current: -54.6
-72.8
-14.7
ROC (Joel Greenblatt) (%) -183.50
DNDN's ROC (Joel Greenblatt) (%) is ranked lower than
740740% of the 135 Companies
in the Global Biotechnology industry.

( Industry Median: 21.60 vs. DNDN: -183.50 )
DNDN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6888.8   Max: -96.8
Current: -183.5
-6888.8
-96.8
EBITDA Growth (%) 23.1
DNDN's EBITDA Growth (%) is ranked higher than
77% of the 99 Companies
in the Global Biotechnology industry.

( Industry Median: 11.00 vs. DNDN: 23.1 )
DNDN' s 10-Year EBITDA Growth (%) Range
Min: -15.2   Max: 211.4
Current: 23.1
-15.2
211.4
EPS Growth (%) 6.8
DNDN's EPS Growth (%) is ranked lower than
76% of the 86 Companies
in the Global Biotechnology industry.

( Industry Median: 12.20 vs. DNDN: 6.8 )
DNDN' s 10-Year EPS Growth (%) Range
Min: -48.4   Max: 30.8
Current: 6.8
-48.4
30.8
ยป DNDN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

DNDN Guru Trades in Q2 2012

Jim Simons 327,269 sh (New)
Steven Cohen 173,800 sh (+1462.11%)
John Burbank 500,000 sh (unchged)
Murray Stahl 29,000 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
Paul Tudor Jones Sold Out
PRIMECAP Management 6,231,930 sh (-28.51%)
» More
Q3 2012

DNDN Guru Trades in Q3 2012

Jim Simons 1,786,900 sh (+446%)
Murray Stahl 29,000 sh (unchged)
Steven Cohen Sold Out
John Burbank Sold Out
PRIMECAP Management 4,427,800 sh (-28.95%)
» More
Q4 2012

DNDN Guru Trades in Q4 2012

Murray Stahl 29,000 sh (unchged)
PRIMECAP Management 3,993,800 sh (-9.8%)
Jim Simons 447,600 sh (-74.95%)
» More
Q1 2013

DNDN Guru Trades in Q1 2013

Steven Cohen 352,600 sh (New)
Murray Stahl 29,000 sh (unchged)
Jim Simons Sold Out
PRIMECAP Management 3,789,800 sh (-5.11%)
» More
» Details

Insider Trades

Latest Guru Trades with DNDN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2012-09-30 Sold Out 0.13%$4.27 - $7.43 $ 3.91-28%0
PRIMECAP Management 2012-09-30 Reduce -28.95%0.02%$4.27 - $7.43 $ 3.91-28%4427800
PRIMECAP Management 2012-06-30 Reduce -28.51%0.04%$5.83 - $11.8 $ 3.91-55%6231930
John Burbank 2012-03-31 New Buy0.18%$7.6 - $16.53 $ 3.91-67%500000
George Soros 2011-12-31 Sold Out 0.03%$6.55 - $11.29 $ 3.91-54%0
George Soros 2011-09-30 Reduce -92.85%1.33%$9.12 - $41.64 $ 3.91-82%185000
George Soros 2011-06-30 Reduce -44.64%1.22%$36.86 - $43.43 $ 3.91-90%2586366
George Soros 2011-03-31 Add 11.27%0.21%$31.85 - $38.2 $ 3.91-89%4671699
PRIMECAP Management 2011-03-31 Add 26.03%0.08%$31.85 - $38.2 $ 3.91-89%7544649
George Soros 2010-12-31 Add 131.15%1.08%$33.84 - $41.22 $ 3.91-90%4198696
George Soros 2010-09-30 New Buy1.12%$27.31 - $42.58 $ 3.91-89%1816463
George Soros 2010-06-30 Sold Out 0.01%$33.59 - $55.43 $ 3.91-90%0
George Soros 2010-03-31 New Buy0.01%$26.28 - $37.818 $ 3.91-88%11938
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/B 17.90
DNDN's P/B is ranked lower than
278551% of the 359 Companies
in the Global Biotechnology industry.

( Industry Median: 3.70 vs. DNDN: 17.90 )
DNDN' s 10-Year P/B Range
Min: 0.71   Max: 200.22
Current: 17.9
0.71
200.22
P/S 1.90
DNDN's P/S is ranked lower than
255102% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 7.53 vs. DNDN: 1.90 )
DNDN' s 10-Year P/S Range
Min: 1.28   Max: 5406
Current: 1.9
1.28
5406
EV-to-EBIT 0.1
DNDN's EV-to-EBIT is ranked lower than
764% of the 266 Companies
in the Global Biotechnology industry.

( Industry Median: 21.21 vs. DNDN: 0.1 )
DNDN' s 10-Year EV-to-EBIT Range
Min: 22.3   Max: 213.4
Current: 0.1
22.3
213.4

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 9.3
DNDN's Price/Net Current Asset Value is ranked lower than
319488% of the 313 Companies
in the Global Biotechnology industry.

( Industry Median: 41.90 vs. DNDN: 9.3 )
DNDN' s 10-Year Price/Net Current Asset Value Range
Min: 12   Max: 876
Current: 9.3
12
876
Price/Tangible Book 17.8
DNDN's Price/Tangible Book is ranked lower than
290697% of the 344 Companies
in the Global Biotechnology industry.

( Industry Median: 4.90 vs. DNDN: 17.8 )
DNDN' s 10-Year Price/Tangible Book Range
Min: 1.9   Max: 23
Current: 17.8
1.9
23
Earnings Yield (Greenblatt) 719.80
DNDN's Earnings Yield (Greenblatt) is ranked lower than
446428% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. DNDN: 719.80 )
DNDN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 733.1
Current: 719.8
0.5
733.1
Forward Rate of Return (Yacktman) -7.61
DNDN's Forward Rate of Return (Yacktman) is ranked lower than
1492536% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. DNDN: -7.61 )
DNDN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -13   Max: 23.6
Current: -7.61
-13
23.6

Business Description

Dendreon Corp, a Delaware corporation, is a biotechnology company focused on the discovery, development and commercialization of novel therapeutics that improve cancer treatment options for patients. Its product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers. PROVENGE (sipuleucel-T), is its first commercialized product licensed by the United States Food and Drug Administration, and is a first in class autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. Prostate cancer is the most common non-skin cancer among men in the United States, with over one million men currently diagnosed with the disease, and the second cause of cancer deaths in men in the United States. The Company owns worldwide rights for PROVENGE. The other potential product candidates are under development or are evaluating include investigational cellular immunotherapies targeted towards HER2/neu for the treatment of patients with bladder, breast, ovarian and other solid tumors, carbonic anhydrase 9 ('CA9'), an antigen highly expressed in renal cell carcinoma; and carcinoembryonic antigen ("CEA"), an antigen expressed in colorectal and other cancers. In addition, the Company is investigating an orally-available small molecule treatment targeting TRPM8 that could be applicable to multiple types of cancer in advanced cancer patients. The Company currently depends on specialized vendor relationships that are not readily replaceable for some of the components for its active immunotherapy candidates. The Company currently has approximately 500,000 combined square feet of manufacturing and office space in the New Jersey Facility, the Orange County Facility, and the Atlanta Facility. Products such as chemotherapeutics, androgen metabolism or androgen receptor antagonists, endothelin A receptor antagonists, antisense compounds, angiogenesis inhibitors and gene therapies for cancer are also under development by a number of companies and could potentially compete with PROVENGE and its other product candidates. The Company's competitors include major pharmaceutical companies. The Company is subject to a variety of federal, state and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials. The Company is also subject to regulation by the Occupational Safety and Health Administration ('OSHA'), and the Environmental Protection Agency ('EPA'), and to regulation under the Toxic Substances Control Act.
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:DNR.Germany
ยป More Articles for DNDN

Headlines

Articles On GuruFocus.com
Idenix: Strong Pipeline Will Reward Investors Apr 24 2012 
Dendreon Could Push Higher If New Drug Trials Succeed Apr 23 2012 
Dendreon Could Slip On Shrinking Market For Provenge Apr 22 2012 
Weekly Guru Bargains Highlights: DNDN, AUQ, RFMD, PT, INFA Jan 16 2012 
PRIMECAP Odyssey Funds Letter to Shareholders, Discusses Health Care, IT Jan 10 2012 
Weekly Guru Bargains Highlights: FTR, HUN, HFC, DNDN, PEGA Jan 09 2012 
Options III: Strategy for the Long Term - Writing Covered Calls Oct 17 2011 
Thursday Value Overview Aug 04 2011 
Wednesday Value Overview Jul 27 2011 
Tuesday Value Overview Jul 26 2011 

More From Our Partners
Bayer's Xofigo Cleared in the US - Analyst Blog May 16 2013 - ZACKS

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial